IBJNews

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.

The experimental medicines will be tested in a trial called DIAN TU involving 160 people with a mutation that guarantees they will develop Alzheimer’s at an early age, perhaps as young as 30, the university said in a statement Wednesday.

If the trial is successful, it may lead to those drugs being widely used for people who may have a family history of the disease. Solanezumab slowed the decline in some patients with mild Alzheimer’s and provided no benefit to more advanced patients, Indianapolis-based Lilly announced in August. On Oct. 8, an independent group of scientists confirmed the findings.

“Trying to prevent Alzheimer’s symptoms from ever occurring is a new strategy,” said John C. Morris, the trial’s principal investigator, in Wednesday’s statement. That will be the goal of the research, he said.

Lilly and Roche, based in Basel, Switzerland, have agreed to make their treatments available for the study at no cost, and will support the trial with grants. Another $4.2 million has been given to the investigation from the Alzheimer’s Association, an advocacy group based in Chicago.

The trial will be conducted by Washington University’s unit of the Dominantly Inherited Alzheimer’s Network, or DIAN, an international group of scientists studying rare genetic mutations that cause the disease. The information gathered in these patients may enable better treatment for all dementia patients.

Roche’s gantenerumab binds to clumps of beta amyloid, a protein thought to cause the disease. The drug is thought to help remove the clumps from the brain, and is in a mid- to late-stage company trial that started in 2010. Lilly's solanezumab removes the beta amyloid before it forms plaques.

Another Lilly drug, called a beta secretase inhibitor, is in testing by the company and may be included in the university research as well, according to Wednesday’s statement. That drug is thought to work by reducing the amount of beta amyloid produced in the brain.

The trial, which may start early next year, will test the medicines in inherited early-onset Alzheimer’s patients. The researchers will see if the treatments can prevent the loss of brain function.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Really, taking someone managing the regulation of Alcohol and making himthe President of an IVY Tech regional campus. Does he have an education background?

  2. Jan, great rant. Now how about you review the report and offer rebuttal of the memo. This might be more conducive to civil discourse than a wild rant with no supporting facts. Perhaps some links to support your assertions would be helpful

  3. I've lived in Indianapolis my whole and been to the track 3 times. Once for a Brickyard, once last year on a practice day for Indy 500, and once when I was a high school student to pick up trash for community service. In the past 11 years, I would say while the IMS is a great venue, there are some upgrades that would show that it's changing with the times, just like the city is. First, take out the bleachers and put in individual seats. Kentucky Motor Speedway has individual seats and they look cool. Fix up the restrooms. Add wi-fi. Like others have suggested, look at bringing in concerts leading up to events. Don't just stick with the country music genre. Pop music would work well too I believe. This will attract more young celebrities to the Indy 500 like the kind that go to the Kentucky Derby. Work with Indy Go to increase the frequency of the bus route to the track during high end events. That way people have other options than worrying about where to park and paying for parking. Then after all of this, look at getting night lights. I think the aforementioned strategies are more necessary than night racing at this point in time.

  4. Talking about congestion ANYWHERE in Indianapolis is absolutely laughable. Sure you may have to wait in 5 minutes of traffic to travel down BR avenue during *peak* times. But that is absolutely nothing compared to actual big cities. Indy is way too suburban to have actual congestion problems. So please, never bring up "congestion" as an excuse to avoid development in Indianapolis. If anything, we could use a little more.

  5. Oh wait. Never mind.

ADVERTISEMENT